WO2018191692A8 - Methods for treating fungal infections - Google Patents

Methods for treating fungal infections Download PDF

Info

Publication number
WO2018191692A8
WO2018191692A8 PCT/US2018/027614 US2018027614W WO2018191692A8 WO 2018191692 A8 WO2018191692 A8 WO 2018191692A8 US 2018027614 W US2018027614 W US 2018027614W WO 2018191692 A8 WO2018191692 A8 WO 2018191692A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fungal infections
treating fungal
salt
subject
Prior art date
Application number
PCT/US2018/027614
Other languages
French (fr)
Other versions
WO2018191692A1 (en
Inventor
Kenneth BARTIZAL
Paul Daruwala
Voon ONG
Original Assignee
Cidara Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics, Inc. filed Critical Cidara Therapeutics, Inc.
Publication of WO2018191692A1 publication Critical patent/WO2018191692A1/en
Publication of WO2018191692A8 publication Critical patent/WO2018191692A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to methods of treating vulvovaginal candidiasis in a subject by subcutaneously administering to the subject CD1 01 in salt or neutral form. In some embodiments, CD101 in salt or neutral form is administered in combination with at least one antifungal agent.
PCT/US2018/027614 2017-04-14 2018-04-13 Methods for treating fungal infections WO2018191692A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762485744P 2017-04-14 2017-04-14
US62/485,744 2017-04-14
US201762541463P 2017-08-04 2017-08-04
US62/541,463 2017-08-04

Publications (2)

Publication Number Publication Date
WO2018191692A1 WO2018191692A1 (en) 2018-10-18
WO2018191692A8 true WO2018191692A8 (en) 2018-12-13

Family

ID=63793003

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/027614 WO2018191692A1 (en) 2017-04-14 2018-04-13 Methods for treating fungal infections

Country Status (1)

Country Link
WO (1) WO2018191692A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3677252B1 (en) 2012-03-19 2023-06-28 Cidara Therapeutics, Inc. Dosing regimens for echinocandin class compounds
WO2017120471A1 (en) 2016-01-08 2017-07-13 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
US11712459B2 (en) 2016-03-16 2023-08-01 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CN111050798A (en) 2017-07-12 2020-04-21 奇达拉治疗公司 Compositions and methods for treating fungal infections
US11524980B2 (en) 2018-06-15 2022-12-13 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0702020D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20100009009A1 (en) * 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
WO2015035102A2 (en) * 2013-09-04 2015-03-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections

Also Published As

Publication number Publication date
WO2018191692A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
WO2018191692A8 (en) Methods for treating fungal infections
EP4331677A3 (en) Methods of treating feline coronavirus infections
MX2023003124A (en) Ophthalmic pharmaceutical compositions and uses relating thereto.
MX2017007392A (en) Treating seizure with recombinant alkaline phosphatase.
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2015010191A (en) Methods of treating microbial infections, including mastitis.
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
MX2018010788A (en) Ophthalmological composition.
MX2019003747A (en) Pyridine compound.
WO2015017607A3 (en) METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS
MX2020001836A (en) Method of treating amyotrophic lateral sclerosis with pridopidine.
WO2018151861A8 (en) Methods of treating schizophrenia
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
WO2019126739A8 (en) Pyrvinium pamoate anti-cancer therapies
MX2020008678A (en) Methods of use for trisubstituted benzotriazole derivatives.
MX2021008738A (en) Melflufen dosage regimens for cancer.
MX2019002369A (en) Compounds for treating diseases associated with a mitochondrial dysfonction.
MX2022006945A (en) Treatments of diabetic macular edema and impaired visual acuity.
MX2018008671A (en) COMPOSITION FOR INCREASING EXPRESSION OF PGC-1a.
MX2019011908A (en) Anti-bacterial peptide macrocycles and use thereof.
MX2021012824A (en) Methods of treating pruritus.
WO2015195684A3 (en) Small molecule anti-scarring agents
WO2015142865A3 (en) Metakaryocidal treatments
MX2018001684A (en) Method of wound healing.
MX2018005940A (en) Sodium channel blocker.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18784787

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18784787

Country of ref document: EP

Kind code of ref document: A1